YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Discover Continuous
Calm In Uveitis

YUTIQ™ is designed to deliver a sustained release of fluocinolone for up to 36 months for patients with chronic noninfectious uveitis affecting the posterior segment of the eye1

This site is intended for US healthcare professionals only.

Contact Us

General Information:
Info@EyePoint.com

Address:
480 Pleasant Street
Suite B300
Watertown, MA 02472

Contact Us

General Information:
Info@EyePoint.com

Address:
480 Pleasant Street
Suite B300
Watertown, MA 02472

This site is intended for US healthcare professionals only.

Proven to reduce uveitis recurrence1

[At 6 months—18% for YUTIQ and 79% for sham [95% Cl*: 60% (41%, 73%)] for study 1 and 22% for YUTIQ and 54% for sham [95% CI: 32% (15%, 48%)] for study 2 (P<0.1). At 12 months—28% for YUTIQ and 86% for sham [95% CI: 58% (40%, 70%)] for study 1 and 33% for YUTIQ and 60% for sham [95% CI: 27% (9%, 43%)] for study 2.]

Extended median time to first recurrence of uveitis1,2

[At 12 months—NE for YUTIQ/92 days for sham in study 1; NE for YUTIQ/187 days for sham in study 2.]

Study design: The efficacy of YUTIQ was assessed in 2 randomized, multicenter, sham-controlled, double-masked, phase 3 studies in adult patients [N=282] with noninfectious uveitis affecting the posterior segment of the eye. The primary endpoint in both studies was the proportion of patients who experienced recurrence of uveitis in the study eye within 6 months of follow-up; recurrence was also assessed at 12 months. Recurrence was defined as either deterioration in visual acuity, vitreous haze attributable to noninfectious uveitis, or the need for rescue medications.1

*Confidence interval.
NE=non-evaluable due to the low number of recurrences in the YUTIQ group.2

Learn how to
administer YUTIQ

YUTIQ is administered in-office under aseptic conditions. To learn more about the YUTIQ administration process, view the administration video or download the injection training brochure.

Learn how to
administer YUTIQ

YUTIQ is administered in-office under aseptic conditions. To learn more about the YUTIQ administration process, view the administration video or download the injection training brochure.

YUTIQ patient support services

We are committed to providing support through every phase of the YUTIQ access process through our complimentary EyePoint AssistSM support program. By offering a range of access and reimbursement resources, we strive to make the patient experience a positive one.

EyePoint Assist will help with coordinating health insurance benefits, determining associated out-of-pocket costs, and assisting in determining eligibility for the YUTIQ co-pay assistance and patient assistance programs.

To learn more, download the resources below or call 1-833-EyePoint (1-833-393-7646; Option 2).

YUTIQ reimbursement and diagnosis codes

An at-a-glance guide designed to provide important codes to properly bill for YUTIQ.

YUTIQ ordering and reimbursement process guide

An overview of the step-by-step ordering and buy-and-bill reimbursement process for YUTIQ.

EyePoint Assist patient enrollment forms

A key component to getting patients started on YUTIQ and enrolled in financial support offerings such as co-pay support.

Patient education

Patient brochure

A patient-friendly resource that provides essential information about chronic noninfectious posterior uveitis and YUTIQ.

Resources

Interested in meeting with an EyePointTM Representative to learn more about YUTIQ?